Anticonvulsant Drugs, Behavior, and Cognitive Abilities

  • Michael Trimble
Chapter
Part of the Current Developments in Psychopharmacology book series (CDPS, volume 6)

Abstract

The literature concerning the relationship of anticonvulsant drugs to disturbances of behavior and cognitive abilities has been reviewed. It is indicated that although completed studies are sparse and although many of the techniques currently used for evaluating the effects of such drugs on patients are inadequate, certain conclusions may be drawn. With regard to the effects on cognitive abilities, the drugs not only impair performance on psychological tests, but some drugs—particularly phenytoin—are associated with a progressive decline of intellectual abilities, which is often insidious and unrecognized. There is little systematic evidence to indicate which anticonvulsant drugs have adverse effects on behavior, but several studies have indicated improvements in behavior associated with carbamazepine and sulthiame.

Keywords

Anticonvulsant Drug Behavior Disorder Epileptic Patient Psychological Test Sodium Valproate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Al-Kaisi, A.M., and McGuire, R.J. (1974). The effect of sulthiame on disturbed behaviour in mentally subnormal patients. Brit. J. Psychiat. 124: 45–49.PubMedGoogle Scholar
  2. Ambrosetto, G., Tassinari, C.A., Baruzzi, A., and Laugaresi, E. (1977). Phenytoin encephalopathy as a probable idiosyncratic reaction. Epilepsia. 18: 405–408.PubMedGoogle Scholar
  3. Barnes, M.., and Fetterman, J.N. (1938). Mentality of dispensary epileptic patients. Arch. Neurol. Psychiat. 40: 903–910.Google Scholar
  4. Barnes, S.E., and Bower, B.D. (1975). Sodium valproate in the treatment of intractable childhood epilepsy. Devel. Med. Child Neurol. 17: 175–181.Google Scholar
  5. Bird, C.A.K., Griffin, B.P., Miklascewska, J.M., and Galbraith, A.W. (1966). Tegretol: A controlled trial of a new anticonvulsant. Brit. J. Psychiat. 112: 737–742.Google Scholar
  6. Bonduelle, M., Bouygues, P., Sallou, C., and Chemal, Y.R. (1964). Clinical trials of an antiepileptic drug G32883. Results of 89 observations. III. Congress of International College of Neuropharmacology. Munich 1962. Elsevier, Amsterdam, pp. 312–316Google Scholar
  7. Bonneycastle, D.D., Giarman, N.J., and Paasonen, M.K. (1957). Anticonvulsant compounds and 5-hydroxytryptamine in rat brain. Brit. J. Pharmacol. 12: 228–231.Google Scholar
  8. Booker, H.E. (1972). Primidone: Toxicity, in Antiepileptic Drugs. D.M. Woodbury, J.K. Penry, and R.P. Schmidt, eds. Raven Press, New York.Google Scholar
  9. Booker, H.E., Matthews, C.G., and Slaby, A. (1967). Effects of diphenylhydantoin on selected physiological-psychological measures in normal adults. Neurol. 17: 949–951.Google Scholar
  10. Boxer, C.M., Herzberg, J.L., and Scott, D.F. (1976). Has sodium valproate hypnotic effects Epilepsia. 17: 367–370.PubMedGoogle Scholar
  11. Browne, T.R., Dreifuss, F.E., Dyken, P.R., Goode, D.J., Penry, J.K. Porter, R.J., White, B.J., and White, P.T. (1975). Ethosuximide in the treatment of absence (petit mal) seizures. Neurol. 25: 515–525.Google Scholar
  12. Cereghino, J.J., Brock, J.T., Van Meter, J.C., Penry, J.R., Smith, L.D., and White, B.G. (1974). Carbamazepine for epilepsy. Neurol. 24: 401–410.Google Scholar
  13. Chadwick, D., Jenner, P., and Reynolds, E.H. (1975). Amines, anticonvulsants, and epilepsy. Lancet. 1: 473–476.Google Scholar
  14. Chanarin, I., Elvas, P.C., and Mollin, D.L. (1958). Folic acid studies in megaloblastic anaemia due to primidone. Brit. Med. J. 2: 80–82.Google Scholar
  15. Chaudhry, M.R., and Pond, D.A. (1961). Mental deterioration in epileptic children. J. Neurol. Neurosurg. Psychiat. 24: 213–219.PubMedGoogle Scholar
  16. Dalby, M.A. (1975). Behavioural effects of carbamazepine, in Advances in Neurology II. J.K. Penry and D.D. Daly, eds. Raven Press, New York.Google Scholar
  17. Dalby, M.A. (1971). Antiepileptic and psychotropic effect of carbamazepine in the treatment of psychomotor epilepsy. Epilepsia. 12: 325–334.PubMedGoogle Scholar
  18. Daneel, A.B. (1967). Tegretol in institutionalised epileptics. S. Afr. Med. J. 41: 772–775.PubMedGoogle Scholar
  19. de Weis, M.L.M., de Monk, C.G., Chardon, M.C., and Waitz, A.M. (1974). Entoque diagnostico y terapeutico del “nino turbulento.” Sem. Med. 144: 9.Google Scholar
  20. Dodrill, C.B. (1975a). DPH serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia. 16: 593–600.PubMedGoogle Scholar
  21. Dodrill, C.B. (1975b). Effects of sulthiame upon intellectual, neuropsychological, and social functioning abilities among adult epileptics: Comparison with diphenylhydantoin. Epilepsia. 16: 617–625.PubMedGoogle Scholar
  22. Finkleman, I., and Arieff, A.J. (1942). Untoward effects of phenytoin sodium in epilepsy. J.A.M.A. 118: 1209–1212.Google Scholar
  23. Fischer, M., Korskjaer, G., and Pedersen, E. (1965). Psychotic episodes in Zarondan treatment. Epilepsia. 6: 325–334.PubMedGoogle Scholar
  24. Fox, J.T. (1924). Response of epileptic children to mental and educational tests. Brit. J. Med. Psychol. 4: 235–248.Google Scholar
  25. Frantzen, E., Hansen, J.M., Hansen, O.E., Kristensen, M. (1967). Phenytoin intoxication. Acta Neuro log. Scand. 43: 440–446.Google Scholar
  26. Glaser, G.H. (1972). Diphenylhydantoin toxicity, in Antiepileptic Drugs. D.M. Woodbury, J.K. Penry, and R.P. Schmidt, eds. Raven Press, New York.Google Scholar
  27. Goode, D.J., Penry, J.K., and Dreifuss, F.E. (1970). Effect of paroxysmal spike wave on continuous visual motor performance. Epilepsia. 11: 241–254.PubMedGoogle Scholar
  28. Gowers, W.R. (1885). Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms, and Treatment. William Wood, London.Google Scholar
  29. Grant, R.H.E. (1974). Sulthiame and behaviour. Devel. Med. Child Neurol. 16: 821–824.Google Scholar
  30. Green, J.R., Troupon, A.S., Halpern, L.M., Friel, P., and Kanarek, P. (1974). Sulthiame: Evaluation as an anticonvulsant. Epilepsia. 15: 329–349.PubMedGoogle Scholar
  31. Grinker, R.R. (1929). The proper use of phenobarbital in the treatment of the epilepsies. J.A.M.A. 93: 1218–1219.Google Scholar
  32. Groh, C.L., Rosenmayr, F., and Birnbaumer, N. (1971). Psychotrope Wirkung von Carbamazepine bie nicht epileptischen. Kind. Med. Monats. 25: 329–333.Google Scholar
  33. Guerrant, J., Anderson, W.W., Fischer, A., Weinstein, M.R., Jarros, R.M., and Deskins, A. (1962). Personality in Epilepsy. Charles C. Thomas, Springfield.Google Scholar
  34. Guey, J., Charles, C., Coquery, C., Roger, J., and Soulayrol, R. (1967). Study of psychological effect of ethosoximide on 25 children suffering from petit mal epilepsy. Epilepsia. 8: 129–141.Google Scholar
  35. Haerer, A.F., and Grace, J.B. (1969). Studies of anticonvulsant levels in epileptics. Acta Neurolog. Scand. 45: 18–31.Google Scholar
  36. Hawkins, C.F., and Meynell, M.J. (1958). Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. Quart. J. Med. 27: 45–63.PubMedGoogle Scholar
  37. Holdsworth, L., and Whitmore, K. (1974). A study of children with epilepsy attending ordinary schools. Devel. Med. Child Neurol. 16: 746–758.Google Scholar
  38. Husby, J. (1963). Delayed toxicity and serum concentrations of phenytoin. Dan. Med. Bull. 10: 236–239.PubMedGoogle Scholar
  39. Hutt, C., Jackson, P.M., and Level, M. (1966). Behavioural parameters and drug effects. Epilepsia. 7: 250–259.PubMedGoogle Scholar
  40. Hutt, S.J., Jackson, P.M., Belsham, A., and Higgins, G. (1968). Perceptual motor behaviour in relation to blood phenobarbitone level. A preliminary report. Devel. Med. Child Neurol. 10: 626–632.Google Scholar
  41. Idestrom, C.M., Schalling, D., Calquist, U., and Sjoquist, F. (1972). Acute effects of diphenyl- hydantoin in relation to plasma levels. Behavioural and psychological studies. Psycholog. Med. 2: 111–120.Google Scholar
  42. Jacobides, G.M. (1966). New uses and some abuses of carbamyldibenzazepine (Tegretol) as a psychotropic agent. Proceedings of the I V World Cbngress of Psychiatry, Madrid.Google Scholar
  43. Jeavons, P.M. (1975). The practical management of epilepsy. Hosp. Update. 1: 11–18.Google Scholar
  44. Kerfriden, P. (1970). Effets psychiques defavorable des medications anticonvitiales. Rev. Neuropsychiat. Infantile. 18: 605–609.Google Scholar
  45. Klein, O.F., and Greenberg, I.M. (1967). Behavioural effects of DPH in severe psychiatric disorders. Am. J. Psychiat. 124: 847–849.PubMedGoogle Scholar
  46. Kooiker, J.C., and Sumi, S.M. (1974). Movement disorder as a manifestation of DPH intoxication. Neurol. 24: 68–71.Google Scholar
  47. Krasovsky, J., Villanueva, R., and Hernandez, O. (1972). La carbamazepine en el tratemiento sintomatico de los trastornos de conducta infantil. Munch. Med. Wochen. 114: 619–622.Google Scholar
  48. Kutt, H., Winters, W., Kokenge, R., and McDowell, F. (1964). Diphenylhydantoin metabolism, blood levels and toxicity. Arch. Neurol. 11: 642–648.PubMedGoogle Scholar
  49. Lennox, W.G. (1942). Brain injury, drugs, and environment as a cause of mental decay in epilepsy. Am. J. Psychiat. 99: 174–180.Google Scholar
  50. Lennox, W.G., and Lennox, M.A. (1960). Epilepsy and Related Disorders. Little, Brown & Co., Boston.Google Scholar
  51. Liu, M.C. (1966). Clinical experience with sulthiame. Brit. J. Psychiat. 112: 621–628.PubMedGoogle Scholar
  52. Livingston, S. (1972). Drug Therapy for Epilepsy. Charles C. Thomas, Springfield.Google Scholar
  53. Logan, W.J., and Freeman, J.M. (1969). Pseudodegenerative disease due to diphenylhydantoin intoxication. Arch. Neurol. 21: 631–637.PubMedGoogle Scholar
  54. Lorentz de Haas, A.M., and Stoel, L.M.K. (1960). Experiences withoethylamethylsuccinimide in the treatment of epilepsy. Epilepsia. 1: 501–511.Google Scholar
  55. Loveland, N., Smith, B., and Forster, F. (1957). Mental and emotional changes in epileptic patients on continuous anticonvulsant medication. Neurol, 7: 856–865.Google Scholar
  56. Mannheimer, E., Packesch, F., Reimer, E.E., and Vetter, H. (1952). Die Haematolgischen Komplikationen der Epilepsiebehandlung mit Hydantoin-korpem. Med. Klinik. 47: 1397–1401.Google Scholar
  57. Marjerrison, G., Jedlicki, S.M., Keogh, R.P., Hrychuk, W., and Poulakakis, G.M. (1968). Carbamazepine: Behavioural, anticonvulsant, and EEG effects in chronically hospitalised epileptics. Dis. Ner. Syst. 29: 133–136.Google Scholar
  58. Matthews, C.G., and Harley, J.P. (1975). Differential psychological test performances in toxic and nontoxic adult epileptics. Neurol. 25: 184–188.Google Scholar
  59. McLellan, D.L., and Swash, M. (1974). Choreoathetosis and encephalopathy induced by Phenytoin. Brit. Med. J. 2: 204–205.PubMedGoogle Scholar
  60. Melamed, E., Reches, A., and Hershko, C. (1975). Reversible cerebral nervous system dysfunction in folate deficiency. J. Neurolog. Sci. 25: 93–98.Google Scholar
  61. Merritt, H.H. (1955). A Textbook of Neurology. Lea and Febiger, Philadelphia.Google Scholar
  62. Millichap, J.G., and Fowler, G.W. (1967). Treatment of “minimal brain dysfunction” syndromes. Paed. Clin. N. Am. 14: 767–777.Google Scholar
  63. Moffatt, W.R., Siddiqui, A.R., and Mackay, D.N. (1970). The use of sulthiame with disturbed mentally subnormal patients. Brit. J. Psychiat. 117: 673–678.PubMedGoogle Scholar
  64. Niedermeyer, E., Blumer, D., Holscher, E., and Walker, B.A. (1970). Classical hysterical seizures precipitated by anticonvulsant toxicity. Psychiatrica Clinica. 3: 71.Google Scholar
  65. Oates, J.A., and Sjoerdsma, A. (1960). Neurological effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurol. 10: 1076–1078.Google Scholar
  66. Ounstead, C. (1955). The hyperkinetic syndrome in epileptic children. Lancet. 2: 303–311.Google Scholar
  67. Parsonage, M. (1975). Treatment with carbamazepine: Adults, in Advances in Neurology, Vol 11. J.K. Penry and D.D. Daly, eds. Raven Press, New York.Google Scholar
  68. Patel, H., and Crichton, J.V. (1968). The neurologic hazards of diphenylhydantoin in childhood. J. Paed. 73: 676–684.Google Scholar
  69. Pereira, J.L.C. (1969). Nossa experiencia com o tegretol nas manifestaçones comiciais näo convulsivas da infancia. O. Hosp. 75: 687–692.Google Scholar
  70. Perlo, V.P., and Schwab, R.S. (1969). Unrecognized dilantin intoxication, in Modern Neurology,, S Locke, ed. Little, Brown & Co., Boston, pp. 589–597.Google Scholar
  71. Prensky, A.L., De Vivo, D.C., and Palkes, H. (1971). Severe bradykinesia as a manifestation of toxicity to antiepileptic medication. J. Paed. 78: 700–704.Google Scholar
  72. Pryse-Phillips, W.E.M., and Jeavons, P.M. (1970). Effect of carbamazepine on the electroen- cephalographic and ward behaviour of patients with chronic epilepsy. Epilepsia. 11: 263–273.PubMedGoogle Scholar
  73. Puente, R.M. (1975). The use of carbamazepine in the treatment of behavioural disorders in children, In Epileptic Seizures—Behaviour—Pain W. Birkmayer, ed. Hans Huber, Stuttgart.Google Scholar
  74. Rajotte, P., Jilek, L., Perales, A., Giard, N., Bordeleau, J.M., and Tetreault, L. (1967). Propriétés antiepileptiques et psychotropes de la carbamazepine. Union Med. Canada. 96: 1200–1206.Google Scholar
  75. Rawson, M.D. (1968). Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurol. 18: 1009–1011.Google Scholar
  76. Rett, A. (1976). The so-called psychotropic effect of tegretol in the treatment of convulsions of cerebral origin in children, In Epileptic Seizures—Behaviour—Pain. W. Birkmayer, ed. Hans Huber, Stuttgart.Google Scholar
  77. Reynolds, E.H. (1967). Schizophrenia-like psychoses of epilepsy and disturbances of folate and B12 metabolism induced by anticonvulsant drugs. Brit. J. Psychiat. 113: 911–919.PubMedGoogle Scholar
  78. Reynolds, E.H. (1970). Iatrogenic disorders in epilepsy, in Modern Trends in Neurology No. 5. D. Williams, ed. Butterworth, London, pp. 271–286.Google Scholar
  79. Reynolds, E.H. (1975a). Chronic antiepileptic toxicity: A review. Epilepsia. 16: 319–353.PubMedGoogle Scholar
  80. Reynolds, E.H. (1975b). In discussion: Behavioural effects of carbamazepine, in Advances in Neurology Vol II. J.K. Penry and D.D. Daly, eds. Raven press, New York. p. 343.Google Scholar
  81. Reynolds, E.H. (1976). Neurological aspects of folate and B12 metabolism. Clin. Haematol. 5: 661–694.PubMedGoogle Scholar
  82. Reynolds, E.H., and Travers, R. (1974). Serum anticonvulsant concentrations in epileptic patients with mental symptoms. Brit. J. Psychiat. 124: 440–445.PubMedGoogle Scholar
  83. Rodin, E.A., Rim, C.S., Kitano, H., Lewis, R., and Rennick, P.M. (1976). A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients. J. Nerv. Ment. Dis. 163: 41–46.PubMedGoogle Scholar
  84. Roger, J., Grangeon, H., Guey, J., and Lob, H. (1968). Psychiatric and psychological effects of ethosuximide treatment in epileptics. Encephale. 57: 407–438.PubMedGoogle Scholar
  85. Roseman, E. (1961). Dilantin toxicity. Neurol. 11: 912–921.Google Scholar
  86. Rosen, J.A. (1968). Dilantin dementia. Trans. Am. Neurolog. Assn. 93: 273.Google Scholar
  87. Royo, D., and Martin, F. (1959). Standardized psychometrical tests applied to the analysis of the effects of anticonvulsant medication on the intellectual proficiency of young epileptics. Epilepsia. 1: 189–207.PubMedGoogle Scholar
  88. Schain, R.J., Ward, J.W., and Guthrie, D. (1977). Carbamazepine as an anticonvulsant in children. Neurol. 27: 476–480.Google Scholar
  89. Schlack, H.G. (1974). Ergenyl in the treatment of epilepsy. Therapiewoche. 24: 39.Google Scholar
  90. Simopoulos, A.M., Pinto, A., Uhlenhuth, E.H., McGee, J.J., and de Rosa, E.R. (1974). D.P.H. effectiveness in the treatment of chronic schizophrenics. Arch. Gen. Psychiat. 30: 106–111.Google Scholar
  91. Smith, W.L., Philipus, M.J., and Guard, H.L. (1968). Psychometric study of children with learning problems and 14 positive spike EEG patterns, treated with ethosuximide (zarontin) and placebo. Arch. Dis. Childhood. 43: 616–619.Google Scholar
  92. Smyth, V.O.G. (1964). The use of ospolot in temporal lobe epilepsy. Epilepsia. 5: 293–295.PubMedGoogle Scholar
  93. Somerfeld-Ziskind, E., and Ziskind, E. (1940). Effect of phenobarbital on the mentality of epileptic patients. Arch. Neurol. Psychiat. 43: 70–79.Google Scholar
  94. Soulayrol, R., and Rbger, J. (1970). Effets psychiatriques defavourables des medicacions antiepileptiques. Rev. Neuropsychiat. Infantile. 18: 599–603.Google Scholar
  95. Stores, G. (1975). Behavioural effects of anticonvulsant drugs. Devel. Med. Child Neurol. 17: 647–658.Google Scholar
  96. Tchicaloff, M., and Gaillard, F. (1970). Quelques effets indesirables des medicaments antiepileptiques sur les rendements intellectuels. Rev. Neuropsychiat. Infantile. 18: 599–603.Google Scholar
  97. Tempkin, O. (1971). The Falling Sickness. Johns Hopkins, Baltimore.Google Scholar
  98. Trimble, M.R. and Corbett, J. (1978a): The effects of anticonvulsant drugs on behaviour. (In preparation.)Google Scholar
  99. Trimble, M.R. and Corbett, J. (1978b). The effects of anticonvulsant drugs on cognitive function. (In preparation.)Google Scholar
  100. Trimble, M.R., Chadwick, D., Reynolds, E.H., and Marsden, C.D. (1975). L-5- hydroxytryptophan and mood. Lancet. 1: 583.PubMedGoogle Scholar
  101. Uhlenhuth, E.H., Stephens, J.H., Dim, B.H.,and Covi, L. (1972). D.P.H. and phenobarbital in the relief of psychoneurotic symptoms. Psychopharmacologia. 27: 67.PubMedGoogle Scholar
  102. Vallarta, J.M., Bell, D.B., and Reichert, A. (1974). Progressive encephalopathy due to chronic hydantoin intoxication. Am. J. Dis. Childhood. 128: 27–34.Google Scholar
  103. Von Last, G. (1972). Epilepsie—Behandlung mit Mylepsinum. Allemeinmedizin/der Landarzt. 7: 336–341.Google Scholar
  104. Wapner, L, Thurston, D.L., and Holowach, J. (1962). Phenobarbital: Its effects on learning in epileptic children. J.A.M.A. 182: 937.PubMedGoogle Scholar
  105. Weiss, C.F., Heffelfinger, J.C., and Buchanan, R.A. (1969). Serial dilantin levels in mentally retarded children. Am. J. Ment. Def 73: 826–830.Google Scholar
  106. Woodbury, D.M., Penry, J.K., and Schmidt, R.P., eds. 1972. Antiepileptic Drugs. Raven Press, New York.Google Scholar

Copyright information

© Spectrum Publications, Inc. 1981

Authors and Affiliations

  • Michael Trimble

There are no affiliations available

Personalised recommendations